The issue here is regulatory compliance, it's a bit hard for me to try interpret/summarise all the laws/regs/guidance available - but in short, there's previously been many controversies about particular public interactions between industry and patients. It's to the point, I know many intentional cultivators have been strongly cautioned not to engage with UK patients whatsoever by Instagram/email etc. For example, even previous MCPA live Zoom discussions I helped arrange and host were being called into question because of mentioning cultivar names (which was being misrepresented as promotional just taking patient questions.)
On the flip side, I hear all the justification for why things should be compliant too. Some companies have quietly stated their interest in interacting with patients directly here - the big consideration is that MedBud needs to practice a high degree of caution not to facilitate any actions which could in some way break the law overall.
If it's possible, we'll get it done - we just also need to be able to provide companies confidence that it would be fully compliant by actually seeking better guidance/advice ourselves first, and figuring out what limitations there would be overall. We'd literally need a stringent rule book for how companies conduct themselves here if viable.
